Tam S, Sabolinski M, Worcel M, Packer M, Cohn J
Clin Pharmacokinet. 2007; 46(10):885-95.
PMID: 17854237
DOI: 10.2165/00003088-200746100-00006.
Reidenberg M
Clin Pharmacokinet. 1993; 24(1):1-9.
PMID: 8448969
DOI: 10.2165/00003088-199324010-00001.
Edstein M, Shanks G, Teja-Isavadharm P, Rieckmann K, Webster H
Br J Clin Pharmacol. 1994; 37(1):67-70.
PMID: 8148220
PMC: 1364712.
DOI: 10.1111/j.1365-2125.1994.tb04241.x.
Ahmad R, Rogers H
Br J Clin Pharmacol. 1980; 10(5):519-24.
PMID: 7437265
PMC: 1430153.
DOI: 10.1111/j.1365-2125.1980.tb01798.x.
Mirkin B, Green T, ODea R
Eur J Clin Pharmacol. 1980; 18(1):109-16.
PMID: 7398740
DOI: 10.1007/BF00561487.
Determination of the acetylator phenotype and pharmacokinetics of some sulphonamides in man.
Vree T, OREILLY W, Hekster Y, Damsma J, van der Kleijn E
Clin Pharmacokinet. 1980; 5(3):274-94.
PMID: 7389236
DOI: 10.2165/00003088-198005030-00006.
Pharmacokinetics of hydralazine and its acid-labile hydrazone metabolites in relation to acetylator phenotype.
Shen D, Hosler J, Schroder R, AZARNOFF D
J Pharmacokinet Biopharm. 1980; 8(1):53-68.
PMID: 7381691
DOI: 10.1007/BF01059448.
Plasma and salivary pharmacokinetics of dapsone estimated by a thin layer chromatographic method.
Ahmad R, Rogers H
Eur J Clin Pharmacol. 1980; 17(2):129-33.
PMID: 7371704
DOI: 10.1007/BF00562621.
Acute low-dose hydralazine induced lupus syndrome (HILS).
Chisholm Jr J
J Natl Med Assoc. 1981; 73(3):278-80.
PMID: 7205989
PMC: 2609808.
Clinical pharmacokinetics of hydralazine.
Ludden T, McNay Jr J, Shepherd A, Lin M
Clin Pharmacokinet. 1982; 7(3):185-205.
PMID: 7047041
DOI: 10.2165/00003088-198207030-00001.
Acquired tolerance to dilator action of hydrallazine during oral administration.
Robinson B, Collier J, Dobbs R
Br J Clin Pharmacol. 1980; 9(4):407-12.
PMID: 6769454
PMC: 1429974.
DOI: 10.1111/j.1365-2125.1980.tb01069.x.
The clinical pharmacology of tolmesoxide. A new vasodilator antihypertensive agent.
OBoyle C, Laher M, OBrien E, OMalley K, Kelly J
Eur J Clin Pharmacol. 1982; 23(2):93-7.
PMID: 6754385
DOI: 10.1007/BF00545961.
Pharmacokinetics of oral hydralazine in chronic heart failure.
Hanson A, Johansson B, Wernersson B, Wahlander L
Eur J Clin Pharmacol. 1983; 25(4):467-73.
PMID: 6653641
DOI: 10.1007/BF00542113.
Prizidilol, a combined vasodilatory and beta-adrenoceptor blocking drug, in primary hypertension. A long-term efficacy, tolerance and pharmacokinetic study.
Karlberg B, Larsson R, Ohman K, Norlander B, Wirsen A, Hed J
Eur J Clin Pharmacol. 1983; 25(2):179-86.
PMID: 6138257
DOI: 10.1007/BF00543788.
Acute effects of prizidilol on blood pressure, heart rate, catecholamines, renin and aldosterone in essential hypertension.
Bianchetti M, Boehringer K, Weidmann P, Link L, Schiffl H, ZIEGLER W
Eur J Clin Pharmacol. 1982; 23(4):289-96.
PMID: 6129141
DOI: 10.1007/BF00613608.
Clinical pharmacokinetics and therapeutic use of hydralazine in congestive heart failure.
Mulrow J, Crawford M
Clin Pharmacokinet. 1989; 16(2):86-9.
PMID: 2656046
DOI: 10.2165/00003088-198916020-00003.
Multiple-dose pharmacokinetics and in vitro antimalarial activity of dapsone plus pyrimethamine (Maloprim) in man.
Edstein M, Rieckmann K, Veenendaal J
Br J Clin Pharmacol. 1990; 30(2):259-65.
PMID: 2206787
PMC: 1368226.
DOI: 10.1111/j.1365-2125.1990.tb03773.x.
Nonlinear pharmacokinetics: clinical Implications.
Ludden T
Clin Pharmacokinet. 1991; 20(6):429-46.
PMID: 2044328
DOI: 10.2165/00003088-199120060-00001.
Drug-related lupus. Incidence, mechanisms and clinical implications.
Adams L, Hess E
Drug Saf. 1991; 6(6):431-49.
PMID: 1793523
DOI: 10.2165/00002018-199106060-00004.
Critical compilation of terminal half-lives, percent excreted unchanged, and changes of half-life in renal and hepatic dysfunction for studies in humans with references.
Pagliaro L, Benet L
J Pharmacokinet Biopharm. 1975; 3(5):333-83.
PMID: 1107513
DOI: 10.1007/BF01082306.
